FINWIRES · TerminalLIVE
FINWIRES

歐洲、中東和非洲地區石油市場最新消息:川普下達封鎖令後,布蘭特原油價格突破100美元大關

-- 週一,受川普下令封鎖霍爾木茲海峽伊朗貨物的影響,布蘭特原油期貨價格上漲約7%,加劇了人們對全球供應長期中斷的擔憂。 布蘭特原油期貨合約上漲約6.7%,至每桶101.58美元。前一周,油價波動劇烈,一度跌破每桶95美元。 穆爾班原油4月10日收在每桶98.16美元,截至發稿時已停止交易。 SEB分析師指出:“今天上午,布蘭特原油6月合約再次上漲7.4%,至每桶102.2美元,原因是周末的談判毫無進展,而美國也宣布封鎖霍爾木茲海峽。目前已明確,封鎖僅針對伊朗貨物。” 油價飆升的主要原因是巴基斯坦伊斯蘭堡高級別談判的徹底破裂。 在副總統約翰·萬斯與伊朗官員進行了長達21小時的馬拉松式會談後,雙方未能就伊朗核計畫和區域衝突達成協議。 作為回應,唐納德·特朗普總統透過社交媒體宣布了一項重大升級措施。 據川普在其「真相社交」(Truth Social)帳號上發布的貼文稱,美國海軍已接到指示,攔截任何試圖進出霍爾木茲海峽且載有伊朗貨物的船隻。 貼文還補充說,美軍將開始摧毀據稱由伊朗佈設在航道上的水雷。 此外,美軍還將搜尋在國際水域向伊朗支付過境「通行費」的船隻,美國稱這些過境費是非法的。 川普總統週日承認了此次行動對國內的影響,並指出汽油和石油價格可能在11月中期選舉前保持在高位。 同時,據報道,伊朗官員警告稱,他們仍然完全控制著水道。

Related Articles

Asia

Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%

Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.

$KOSDAQ:440110
Asia

ASX Biggest Losers

Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07

$^AXJO$ASX:COH$ASX:EVT$ASX:NXG$ASX:ORG$ASX:PDN$ASX:RHC$ASX:SX2$ASX:TLX$ASX:TUA$ASX:WTC
Asia

Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal

Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.

$BOM:524715$NSE:SUNPHARMA